Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy.
Yuichiro KikawaYasuhiro HagiwaraTomomi FujisawaKazuhiro ArakiTakayuki IwamotoTakafumi SangaiTadahiko ShienShintaro TakaoReiki NishimuraMasato TakahashiTatsuya ToyamaTomohiko AiharaHirofumi MukaiNaruto TairaPublished in: PloS one (2022)
Maintaining the HRQOL as determined by FACT-ES may be associated with clinical benefits in patients with acquired endocrine-resistant MBC treated with ET.